Macrolides are a class of protein synthesis inhibitors with wide clinical application value. Since the earliest macrolide erythromycin was discovered in 1950, in order to obtain compounds with better availability and acid stability in medical applications, scientists have continuously synthesized new macrolide derivatives. However, most of the improvements are accompanied by severe side effects. In recent years, the development of hapten technology has introduced a new chemical platform for the synthesis and discovery of a variety of macrolide antibiotics. Creative Biolabs, through the assembly and assembly of simple chemical structural units, has established a highly efficient macrolide antibiotic design scheme and synthetic pathway, which represents the renaissance of macrolide drugs, helping researchers to develop new and safe therapeutic agents and enhance hope for a fight against serious human infectious diseases. Macrolides (MALs) Hapten Synthesis https://small-molecule-antibody.creative-biolabs.com/macrolides-mals-hapten-design-and-synthesis.htm